Identification
Name2-{4-[(2s)-2-[({[(1s)-1-Carboxy-2-Phenylethyl]Amino}Carbonyl)Amino]-3-Oxo-3-(Pentylamino)Propyl]Phenoxy}Malonic Acid
Accession NumberDB02436  (EXPT01899)
TypeSmall Molecule
GroupsExperimental
DescriptionNot Available
Structure
Thumb
SynonymsNot Available
External IDs Not Available
Product Ingredients Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
CategoriesNot Available
UNIINot Available
CAS numberNot Available
WeightAverage: 543.5656
Monoisotopic: 543.221679669
Chemical FormulaC27H33N3O9
InChI KeyBKONADSQADEJJP-SFTDATJTSA-N
InChI
InChI=1S/C27H33N3O9/c1-2-3-7-14-28-23(31)20(15-18-10-12-19(13-11-18)39-22(25(34)35)26(36)37)29-27(38)30-21(24(32)33)16-17-8-5-4-6-9-17/h4-6,8-13,20-22H,2-3,7,14-16H2,1H3,(H,28,31)(H,32,33)(H,34,35)(H,36,37)(H2,29,30,38)/t20-,21-/m0/s1
IUPAC Name
2-{4-[(2S)-2-{N-[(1S)-1-carboxy-2-phenylethyl]-(C-hydroxycarbonimidoyl)amino}-2-(pentyl-C-hydroxycarbonimidoyl)ethyl]phenoxy}propanedioic acid
SMILES
[H][C@@](CC1=CC=CC=C1)(NC(O)=N[C@@]([H])(CC1=CC=C(OC(C(O)=O)C(O)=O)C=C1)C(O)=NCCCCC)C(O)=O
Pharmacology
IndicationNot Available
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of action
TargetKindPharmacological actionActionsOrganismUniProt ID
Tyrosine-protein phosphatase non-receptor type 1ProteinunknownNot AvailableHumanP18031 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions Not Available
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB Entries
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials Not Available
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.0108 mg/mLALOGPS
logP2.16ALOGPS
logP2.78ChemAxon
logS-4.7ALOGPS
pKa (Strongest Acidic)2.08ChemAxon
pKa (Strongest Basic)5.91ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count12ChemAxon
Hydrogen Donor Count6ChemAxon
Polar Surface Area198.34 Å2ChemAxon
Rotatable Bond Count16ChemAxon
Refractivity138.1 m3·mol-1ChemAxon
Polarizability55.01 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.8472
Blood Brain Barrier-0.7404
Caco-2 permeable-0.6906
P-glycoprotein substrateSubstrate0.8929
P-glycoprotein inhibitor INon-inhibitor0.8216
P-glycoprotein inhibitor IINon-inhibitor0.8156
Renal organic cation transporterNon-inhibitor0.8862
CYP450 2C9 substrateNon-substrate0.659
CYP450 2D6 substrateNon-substrate0.77
CYP450 3A4 substrateNon-substrate0.5838
CYP450 1A2 substrateNon-inhibitor0.8626
CYP450 2C9 inhibitorNon-inhibitor0.7541
CYP450 2D6 inhibitorNon-inhibitor0.7529
CYP450 2C19 inhibitorNon-inhibitor0.6695
CYP450 3A4 inhibitorInhibitor0.5112
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6597
Ames testNon AMES toxic0.7892
CarcinogenicityNon-carcinogens0.9053
BiodegradationNot ready biodegradable0.7033
Rat acute toxicity2.4279 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9405
hERG inhibition (predictor II)Non-inhibitor0.6477
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of chemical entities known as phenylalanine and derivatives. These are compounds containing phenylalanine or a derivative thereof resulting from reaction of phenylalanine at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.
KingdomChemical entities
Super ClassOrganic compounds
ClassOrganic acids and derivatives
Sub ClassCarboxylic acids and derivatives
Direct ParentPhenylalanine and derivatives
Alternative ParentsN-carbamoyl-alpha amino acids / Alpha amino acid amides / Phenylpropanoic acids / Phenoxyacetic acid derivatives / Amphetamines and derivatives / Tricarboxylic acids and derivatives / Phenoxy compounds / Phenol ethers / Alkyl aryl ethers / 1,3-dicarbonyl compounds
SubstituentsPhenylalanine or derivatives / N-carbamoyl-alpha-amino acid / N-carbamoyl-alpha-amino acid or derivatives / Alpha-amino acid amide / Phenoxyacetate / 3-phenylpropanoic-acid / Amphetamine or derivatives / Tricarboxylic acid or derivatives / Phenoxy compound / Phenol ether
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Zinc ion binding
Specific Function:
Tyrosine-protein phosphatase which acts as a regulator of endoplasmic reticulum unfolded protein response. Mediates dephosphorylation of EIF2AK3/PERK; inactivating the protein kinase activity of EIF2AK3/PERK. May play an important role in CKII- and p60c-src-induced signal transduction cascades. May regulate the EFNA5-EPHA3 signaling pathway which modulates cell reorganization and cell-cell repu...
Gene Name:
PTPN1
Uniprot ID:
P18031
Molecular Weight:
49966.44 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Drug created on June 13, 2005 07:24 / Updated on July 18, 2017 17:09